U.S. markets open in 7 hours 14 minutes

Glucose Health, Inc. (GLUC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6490+0.0090 (+1.41%)
At close: 03:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6389 - 0.6490
52 Week Range0.4300 - 3.2450
Avg. Volume15,667
Market Cap2.95M
Beta (5Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateAug 22, 2022 - Aug 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GLUC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: AMETEK, Inc.Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm’s sales are made in the United States. The firm’s asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • GlobeNewswire

    Glucose Health, Inc. Corporate Update

    BENTONVILLE, AR, March 24, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC Pink: GLUC) ("Company") today provided the following corporate update, in response to requests from shareholders and interested parties for clarification of recent corporate events. John Fieldly, the current Chief Executive Officer of Celsius Holdings, Inc. (Celsius), Hal Kravitz, a current member of the Board of Directors of Celsius, and Gerry David, the former Chief Executive Officer of Celsius, comprised the indepen

  • GlobeNewswire

    Glucose Health, Inc. Fiscal 2021 Annual Report

    BENTONVILLE, AR, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) ("Company") is pleased to highlight selected financial metrics presented in its Fiscal 2021 Annual Report posted today at In fiscal 2021, Glucose Health, Inc. more than doubled gross profits, effectively doubled revenue, and achieved the unique status of a debt free, emerging growth, company. Fiscal 2021 Revenue of $953,681 vs. $480,713 for Fiscal 2020 = a 98% increase.Fiscal 2021 Gross Profit of

  • GlobeNewswire

    Glucose Health, Inc. USPTO Patent Filing Asserts First Use of Nutritional Composition Underlying GLUCODOWN®

    BENTONVILLE, AR, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC Pink: GLUC) ("Company") is pleased to advise that a patent application for "Compositions and Methods for Metabolic Health" was filed with the United States Trademark and Patent Office (USPTO) on December 23, 2021, on behalf of the Company. The patent filing discloses a composition of the combination of resistant dextrin, corosolic acid and chromium picolinate, in measures for maintaining and improving health by attenuat